Iovance Biotherapeutics has carved out a piece of biotech history, becoming the first company to win FDA clearance for a cell therapy used to treat a solid tumour.
Just a week after dropping the development of its CD47-targeting antibody magrolimab in blood cancers, Gilead Sciences has paused enrolment in clinical trials of the drug
Astellas has signed an R&D and licensing deal with Kelonia Therapeutics that aims to develop CAR-T therapies for cancer that will push the boundaries of what can be ac
Healthtech consultancy Innsena has committed funding and expertise to The White House’s CancerX initiative, launched last year to encourage the use of digital technologies
Roche has turned to artificial intelligence specialist PathAI to accelerate development of digital pathology technologies that can be used to match patients with drug treatments and s
Gilead Sciences has said it will no longer develop its CD47-targeting antibody magrolimab in blood cancers after data suggested that patients taking the drug in clinical t